Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 26, 2022

NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  which will be held October 26-28, 2022 at the CCIB in Barcelona.

Details of the upcoming presentation are as follows:

Title:  NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor
Presenter: Paola Magnaghi, Biomolecular Engineering Lab Head, NMS Srl
Poster #: 48
Session: Molecular Targeted Agents 1
Session Date/Time: Wednesday, 26 October 2022, All day
Location: Exhibition Hall

About NMS-03602173 (NMS-173)

NMS-173 is a second generation potent, covalent, selective, and orally available investigational new drug for the treatment of cancer patients with mutated IDH1 or IDH2. IDH1 and IDH2 mutations confer to these enzymes a neomorphic activity promoting the conversion of α-KG into 2-HG, an oncometabolite that induces a global epigenetic rewiring, leading to de-differentiation, stemness and tumorigenesis. NMS-173 potently inhibits mutant IDH1 and IDH2 thus resulting in the abrogation of 2-HG production in a variety of cells and in a number of in vivo mouse models including IDH mutant cholangiocarcinoma, glioma and AML models, with significant tumor growth inhibition and anti-tumor efficacy superior to FDA approved first generation inhibitors. Due to its covalent MOA, NMS-173 has high potential of sustained clinical responses compared to FDA approved drugs and can also potentially overcome resistance mechanisms to first generation IDH inhibitors. Notably, NMS-173 has received authorization to start phase I clinical studies in US and Europe in patients with IDH1 or IDH2 mutated solid tumors including low grade glioma.

Link: 20221025-IDH-ENA2022



Welcome and Check out our new motion picture!